Gefitinib Versus Pemetrexed for Previously Treated NSCLC Patients

Gachon University Gil Medical Center

Status and phase: Completed; Phase 2

Conditions: Previous Treated Metastatic Non-small Cell Lung Cancer

Treatments: Drug: Gefitinib; Drug: Pemetrexed

Study type: Interventional

Funder types: Other

Identifiers

NCT01783834

2008-GIRBA-1739

Details and patient eligibility

About

To compare the efficacy of gefitinib versus pemetrexed as second-line chemotherapy for patients with previous treated non-small cell lung cancer

Enrollment: 95 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Cells pathologically diagnosed as histological or radical surgery or radiation therapy is not possible stage IIIB and stage IV non-small-cell lung cancer patients
• second line
• ECOG 0～2
• Patients with normal liver function and renal function

Exclusion criteria

• Patients with severe acute infection requiring antibiotic therapy
• Patients who have received treatment in other areas of cancer within 5 years
• During pregnancy and lactation patients

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

95 participants in 2 patient groups

pemetrexed

Active Comparator group

Description:

pemetrexed

Treatment:

Drug: Pemetrexed

gefitinib

Active Comparator group

Description:

gefitinib

Treatment:

Drug: Gefitinib